Get started
Author

Franziska Briest

Observed names: Briest, F., Briest, Franziska, Briest, Franziska Katharina, F Briest, F. Briest, FRANZISKA BRIEST
Observed institutions: Humboldt-Universität zu Berlin, Zentralklinik Bad Berka, Jena University Hospital, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Stiftung Charité, Freie Universität Berlin, Charité - Universitätsmedizin Berlin
ORCID: 0000-0001-5969-9467
Observed ORCID: 0000-0001-5969-9467
OpenAlex ID: A5073828162
PI3K-AKT-mTOR-Signaling and beyond: the Complex Network in Gastroenteropancreatic Neuroendocrine Neoplasms
2014 · Franziska Briest, Patricia Grabowski · Theranostics · 89
PDF
Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes
2023 · Daniel Noerenberg, Franziska Briest, et al. · Journal of Clinical Oncology · 36
The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models
2017 · Svenja Nölting, Jakob Rentsch, et al. · PLoS ONE · 34
PDF
Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease
2016 · Helma Freitag, Friederike Christen, et al. · Neuroendocrinology · 33
Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer
2017 · Sanaz Taromi, Florentine Lewens, et al. · Oncotarget · 31
PDF
FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumors
2015 · Franziska Briest, Erika Berg, et al. · Oncotarget · 28
A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial
2021 · K. Hoyer, R. Hablesreiter, et al. · EBioMedicine · 27
PDF
The p53 network as therapeutic target in gastroenteropancreatic neuroendocrine neoplasms
2015 · Franziska Briest, Patricia Grabowski · Cancer Treatment Reviews · 26
Immunoprofiling in Neuroendocrine Neoplasms Unveil Immunosuppressive Microenvironment
2020 · Antonia Busse, Liliana H. Mochmann, et al. · Cancers · 24
PDF
Modeling clonal hematopoiesis in umbilical cord blood cells by CRISPR/Cas9
2021 · Friederike Christen, Raphael Hablesreiter, et al. · Leukemia · 21
PDF
Mechanisms of Targeting the MDM2-p53-FOXM1 Axis in Well-Differentiated Intestinal Neuroendocrine Tumors
2017 · Franziska Briest, Irina Grass, et al. · Neuroendocrinology · 14
PDF
Vandetanib therapy in medullary thyroid cancer
2012 · Grabowski, P., Briest, F., et al. · Drugs of today · 14
Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma
2023 · Franziska Briest, Daniel Noerenberg, et al. · Leukemia · 12
PDF
Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? – A preclinical assessment in vitro and in vivo
2020 · Franziska Briest, Eva J. Koziolek, et al. · Neoplasia · 11
PDF
Tumor-stroma interactions in tumorigenesis: lessons from stem cell biology
2011 · Franziska Briest · Frontiers in Bioscience-Elite · 11
PDF
Clonal hematopoiesis and lymphoma-associated mutations in hematopoietic progenitors in B-cell non-Hodgkin lymphoma
2026 · Laura Wiegand, Patricia Silva, et al. · Blood · 10
Concomitant inhibition of PI3K/mTOR signaling pathways boosts antiproliferative effects of lanreotide in bronchopulmonary neuroendocrine tumor cells
2024 · Claus von Hessert-Vaudoncourt, Sara Lelek, et al. · Frontiers in Pharmacology · 7
PDF
Immunohistochemical Study of Mitosis-regulatory Proteins in Gastroenteropancreatic Neuroendocrine Neoplasms
2018 · FRANZISKA BRIEST, YAWEN WANG, et al. · Anticancer Research · 7
PDF
455 Role of MDM2 as therapeutic target in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs)
2014 · F. Briest, I. Grass, et al. · European Journal of Cancer · 3
Tracing Clonal Hematopoiesis and Tumor-Specific Mutations in Hematopoietic Progenitors of B Cell Non-Hodgkin Lymphoma (NHL) Patients
2024 · Laura Wiegand, Patricia Silva, et al. · Blood · 2
S101: Genetic and Epigenetic Factors Driving Primary Mediastinal B-cell Lymphoma Pathogenesis and Outcome
2022 · D. Noerenberg, F. Briest, et al. · HemaSphere · 2
Concomitant inhibition of PI3K/mTOR signaling pathways boosts antiproliferative effects of lanreotide in bronchopulmonary neuroendocrine tumor cells
2024 · von Hessert-Vaudoncourt, Claus, Lelek, Sara, et al. · Zurich Open Repository and Archive (University of Zurich)
Abstract LBA043: mRNA expression of mTOR signaling components as potential predictive biomarker in pancreatic neuroendocrine neoplasms
2021 · Sebastian Wolfshöfer, Adrian C Lock, et al. · Molecular Cancer Therapeutics
Supplementary Material for: Mechanisms of Targeting the MDM2-p53-FOXM1 Axis in Well-Differentiated Intestinal Neuroendocrine Tumors
2017 · Briest, F., Grass, I., et al. · Figshare
Immunohistochemical study of AuroraB proves association with differentiation and expression of crucial progression markers in gastroenteropancreatic neuroendocrine neoplasms
2016 · Yawen Wang, Franziska Briest, et al. · Endocrine Abstracts
PDF
Works count: 34
Citation count: 441
H-index: 13
I10-index: 16
Year
Topic
Type